{"id":"NCT01949311","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Open-label Study of Dupilumab in Patients With Atopic Dermatitis","officialTitle":"An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-10","primaryCompletion":"2022-06-27","completion":"2022-06-27","firstPosted":"2013-09-24","resultsPosted":"2023-10-17","lastUpdate":"2023-10-17"},"enrollment":2733,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["DUPIXENTÂ®","REGN668","SAR231893"]}],"arms":[{"label":"Dupilumab","type":"EXPERIMENTAL"}],"summary":"The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD).\n\nThe secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment.\n\nOptional Sub-Study:\n\nThe primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product.\n\nThe secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.","primaryOutcome":{"measure":"Number of Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 272 weeks","effectByArm":[{"arm":"Dupilumab","deltaMin":14717,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":432,"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","China","Czechia","Denmark","Estonia","Finland","France","Germany","Hungary","Ireland","Italy","Japan","Lithuania","Netherlands","New Zealand","Poland","Romania","Russia","Singapore","Slovakia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["39588375","36318387","35636689","35503163","34897582","34714527","33557637","32557382"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":283,"n":2677},"commonTop":["Nasopharyngitis","Dermatitis atopic","Upper respiratory tract infection","Conjunctivitis","Conjunctivitis allergic"]}}